It is also important to note that although mutations in TET genes are frequently found in AML without IDH1/2 mutations, they are extremely rare in CS and therefore such mutations are unlikely to account for a common pathogenic alternative to IDH mutation in this cancer. This evidence concerns the gene IDH1 and acute myeloid leukemia.